This video from ACC 2026 examines practical challenges in implementing cardiac myosin inhibitor therapy for patients with hypertrophic cardiomyopathy. Dr. Florian Rader reviews how these agents target underlying disease pathophysiology and outlines common barriers to initiation, including REMS requirements, monitoring logistics, and workflow integration. Key insights emphasize minimizing delays and ensuring that eligible patients can access appropriate disease-targeted therapy. Tune in to see how these approaches can be applied in your practice.
advertisement
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Share
Save
Restart
Resume
Transcript
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
closeTranscript
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
closeTranscript
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
closeDr. Rader:
Hello from ACC 2026 here in New Orleans. I'm Dr. Florian Rader, and I'm the director of the HCM Center at Cedars-Sinai in Los Angeles.
The field of hypertrophic cardiomyopathy, or HCM, has evolved tremendously with new therapies already available or several others in development as we speak. Cardiac myosin inhibitors, which target some of the underlying mechanisms of HCM, are incredibly effective and help patients live a better life. However, getting patients on these treatments isn't always straightforward, so let's talk about how we can overcome those barriers and ensure timely use of cardiac myosin inhibitors in the appropriate patients.
So cardiac myosin inhibitors are only available through a REMS program. The REMS stands for risk evaluation and mitigation. And although these REMS programs make sure that cardiac myosin inhibitors are being prescribed in a safe manner and they really work, it can also delay treatment or cause pause in some prescribers, who may just choose to stick with beta-blockers, which are just simply easier to prescribe.
However, recent data have shown that these beta-blockers, for example, are not nearly as effective as cardiac myosin inhibitors. Therefore, between clinical inertia and difficulties with insurance coverage, access to myosin inhibitors can really be a challenge.
To overcome these barriers, working together with an HCM specialty center can help provide optimal treatment for patients so they can feel their best and have the optimal outcomes we wish for. HCM centers are not only experienced with prescribing myosin inhibitors but also are more experienced to get those medications approved by insurances.
So if I have one call to action today, it would be don't let logistical complexity drive therapeutic inertia. Make sure you're taking the necessary steps to either navigate the REMS or collaborate with an HCM center that is experienced with the REMS program and prescribing cardiac myosin inhibitors.
From ACC 2026, I'm Dr. Florian Rader, and thank you for watching.
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Related
Overview
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Recommended
Details
Presenters
Related
Overview
This video from ACC 2026 examines practical challenges in implementing cardiac myosin inhibitor therapy for patients with hypertrophic cardiomyopathy. Dr. Florian Rader reviews how these agents target underlying disease pathophysiology and outlines common barriers to initiation, including REMS requirements, monitoring logistics, and workflow integration. Key insights emphasize minimizing delays and ensuring that eligible patients can access appropriate disease-targeted therapy. Tune in to see how these approaches can be applied in your practice.
Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?